Patents by Inventor Sea Gwang PARK

Sea Gwang PARK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition for preventing or treating neovascular disease, containing collagen type i and pigment epithelium derived factor peptide as active ingredients
    Patent number: 11197918
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neovascular disease, including a collagen and a 34-mer pigment epithelium derived factor (PEDF) peptide as an active ingredient, more specifically, the combined administration of the collagen type I and the 34-mer pigment epithelium derived factor peptide increases the short antiangiogenic activity cycle of the PEDF and extends the dosage range of the PEDF to solve the discomfort and the side effects accordingly due to the conventional frequent injections and thus it can be applied as a therapeutic agent for various neovascular diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: December 14, 2021
    Assignee: NexThera Co., Ltd.
    Inventors: Sea Gwang Park, Kug Hwan Roh, Hyun Woong Kim, Sung Jae Park
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEOVASCULAR DISEASE, CONTAINING COLLAGEN TYPE I AND PIGMENT EPITHELIUM DERIVED FACTOR PEPTIDE AS ACTIVE INGREDIENTS
    Publication number: 20210077599
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neovascular disease, including a collagen and a 34-mer pigment epithelium derived factor (PEDF) peptide as an active ingredient, more specifically, the combined administration of the collagen type I and the 34-mer pigment epithelium derived factor peptide increases the short antiangiogenic activity cycle of the PEDF and extends the dosage range of the PEDF to solve the discomfort and the side effects accordingly due to the conventional frequent injections and thus it can be applied as a therapeutic agent for various neovascular diseases.
    Type: Application
    Filed: June 8, 2018
    Publication date: March 18, 2021
    Applicant: INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Sea Gwang PARK, Kug Hwan ROH, Hyun Woong KIM, Sung Jae PARK